The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Open accessAbstract
OBJECTIVE: Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. METHOD: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1). RESULTS: The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75). The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0). Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score. Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up. CONCLUSIONS: Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an NMDA glutamate receptor antagonist, reduced suicidal ideation within 1–4 hours in major depression(71–75) and bipolar disorder.(76, 77)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [72]
In the citing paper
“Furthermore, ketamine has been reported to also have anti-suicidal and anti-anhedonic actions.14,19,20”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [19]
In the citing paper
“Thirdly, samples were usually small.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Firstly, the suicidal risk was often poorly measured (eg, with one single item of a depression scale).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Recently, ketamine has been shown to have a rapid effect on depressive symptoms and suicidal ideation after a single dose.8 9 10 11”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Secondly, response (usually defined as a 50% score reduction on a scale) was the most common outcome rather than remission (that is, complete absence of suicidal ideas).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“The persistence of the ketamine effect at six weeks of intake is not in line with previous studies10 11 31 and the related meta-analysis,12 but those three studies together analysed only 63 patients.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Altered expression of glutamate receptor N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite glutamate receptors is linked to suicidal behavior (129) and may play a role in the rapid-onset antidepressant and antisuicidal effects of ketamine (130-135).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
In the citing paper
“The anti–suicidal ideation effect of ketamine is only partly explained by its antidepressant action, and effects on memory and cognition may also play a role (131-133).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
In the citing paper
“Intravenous ketamine is a rapidly acting treatment that robustly reduces depressive symptoms and suicidal ideation in hours instead of weeks (130-133).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Research works printed but not linked: 7
- Prudic J, 1999, J Clin Psychiatry, 60, 104
- 10.1037/0022-006X.47.2.343 · DOI · Paper page
- First MB, 1994, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
- First MB, 1996, Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (Version 2.0)
- McNair DM, 1981, Manual for the Profile of Mood States
- Levine J, 1986, Psychopharmacol Bull, 22, 343
- Muthén LK, 2012, Mplus User’s Guide
Cited by
Sorted by citations
Items 101–200 of 430
The impact of sex as a biological variable in the search for novel antidepressants
Williams, A. V., & Trainor, B. C. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.05.003 · Cited by 42
A meta-analysis of the effects of ketamine on suicidal ideation in depression patients
Shen, Z., Gao, D., Lv, X., Wang, H., & Yue, W. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02973-1 · Cited by 41
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 43
Li, L. R., Sethi, G., Zhang, X., Liu, C. L., Yan, H., Liu, Q., Ren, B. X., & Tang, F. R. (2022) · Aging · doi:10.18632/aging.203893 · Cited by 41
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 39
Anesthetics: from modes of action to unconsciousness and neurotoxicity
Iqbal, F., Thompson, A. J., Riaz, S., Pehar, M., Rice, T. K., & Syed, N. I. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00210.2019 · Cited by 37
High-Dose Ketamine Infusion for the Treatment of Posttraumatic Stress Disorder in Combat Veterans
Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019) · Annals of Clinical Psychiatry · doi:10.1177/154733251903100411 · Cited by 36
Repurposing of Drugs–The Ketamine Story
Das, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01193 · Cited by 41
Nobile, B., Olié, É., Dubois, J., Guillaume, S., Gorwood, P. A. P. M., & Courtet, P. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211025697 · Cited by 37
Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression
Dai, D., Lacadie, C. M., Holmes, S. E., Cool, R., Anticevic, A., Averill, C., Abdallah, C., & Esterlis, I. (2020) · Chronic Stress · doi:10.1177/2470547020980681 · Cited by 34
Feeney, A., Hock, R., Freeman, M. P., Flynn, M., Hoeppner, B., Iosifescu, D., Trivedi, M., Sanacora, G., Mathew, S., DeBattista, C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.024 · Cited by 33
de la Salle, S., Phillips, J. L., Blier, P., & Knott, V. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110507 · Cited by 37
Averill, L. A., Averill, C. L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.-H., Ranganathan, M., D'Souza, D. C., Southwick, S. M., Sanacora, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.01.104 · Cited by 33
Calder, C. N., Kwan, A. T. H., Teopiz, K. M., Wong, S., Rosenblat, J. D., Mansur, R. B., Rhee, T. G., Ho, R., Cao, B., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.039 · Cited by 37
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021004 · Cited by 34
Self-citationBaojuan Li, A., Zhao, N., Tang, N., Friston, K. J., Zhai, W., Wu, D., Liu, J., Chen, Y., Yan, M., Qiao, Y., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-023-02707-9 · Cited by 34
Repurposing Potential of Ketamine: Opportunities and Challenges
Gautam, C. S., Mahajan, S. S., Sharma, J., Singh, H., & Singh, J. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_228_19 · Cited by 32
Ketamine for depression clinical issues
Iqbal, S., & Mathew, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.005 · Cited by 33
Domany, Y., & McCullumsmith, C. B. (2021) · Archives of Suicide Research · doi:10.1080/13811118.2021.1878078 · Cited by 33
Lascelles, K. M., Marzano, L., Brand, F., Trueman, H., McShane, R. H., & Hawton, K. E. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029108 · Cited by 34
Okada, M., Kawano, Y., Fukuyama, K., Motomura, E., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217951 · Cited by 32
Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review
Song, B., & Zhu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.782457 · Cited by 31
Vankawala, J., Naples, G., Avila-Quintero, V. J., Ramírez, K. L., Flores, J. M., Bloch, M. H., & Dwyer, J. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.549080 · Cited by 30
Chen, H., Li, W., Cao, X., Liu, P., Liu, J., Chen, X., Luo, C., Liang, X., Guo, H., Zhong, S., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.745470 · Cited by 29
Chen, C., Zhou, N., Hu, N., Feng, J., & Wang, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s401032 · Cited by 37
Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option
Hermens, D. F., Simcock, G. P., Dutton, M., Bouças, A. P., Can, A., Lilley, C. J., & Lagopoulos, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109921 · Cited by 30
Vieira, F., Correia‐Melo, F. S., Santos‐Lima, C., Souza‐Marques, B., Leal, G. C.-G., Jesus‐Nunes, A. P., Mello, R. P., Caliman‐Fontes, A. T., Bandeira, I. D., Marback, R. F., et al. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.12.011 · Cited by 29
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 33
Jollant, F., Perreira, F., Fiori, L. M., Richard-Devantoy, S., Lutz, P.-E., Belzeaux, R., & Turecki, G. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109909 · Cited by 25
Effects of somatic treatments on suicidal ideation and completed suicides
Hawkins, E. M., Coryell, W. H., Leung, S., Parikh, S. V., Weston, C. L., Nestadt, P. S., Nürnberger, J. I., Kaplin, A. I., Kumar, A., Farooqui, A. A., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2381 · Cited by 28
Citrome, L., DiBernardo, A., & Singh, J. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 27
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression
Hochschild, A., Keilp, J. G., Madden, S. P., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.055 · Cited by 25
Self-citationLengvenytė, A., Olié, É., Strumila, R., Navickas, A., González-Pinto, A. M., & Courtet, P. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1907712 · Cited by 26
Adhikari, B. M., Dukart, J., Hipp, J. F., Forsyth, A., McMillan, R. L., Muthukumaraswamy, S. D., Ryan, M. C., Hong, L. E., Eickhoff, S. B., Jahandshad, N., et al. (2019) · Human Brain Mapping · doi:10.1002/hbm.24838 · Cited by 23
Terasaki, D., Loh, R. M., Cornell, A., Taub, J., & Thurstone, C. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00345-y · Cited by 25
Ahmed, G. K., Elserogy, Y., Elfadl, G. M. A., Abdelsalam, K. G., & Ali, M. A. S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.005 · Cited by 27
Brent, D. A., Oquendo, M. A., & Reynolds, C. F. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0927 · Cited by 23
Self-citationHippocampal neuropathology in suicide: Gaps in our knowledge and opportunities for a breakthrough
Zhang, L., Lucassen, P. J., Salta, E., Verhaert, P. D. E. M., & Swaab, D. F. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.023 · Cited by 22
Lascelles, K., Marzano, L., Brand, F., Trueman, H., McShane, R., & Hawton, K. (2020) · BJPsych Open · doi:10.1192/bjo.2020.132 · Cited by 19
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 24
Li, W., Wang, C., Lan, X., Fu, L., Zhang, F., Ye, Y., Liu, H., Zhou, Y., & Ning, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.07.001 · Cited by 24
La douleur sociale au centre des conduites suicidaires
Courtet, P., & Olié, É. (2018) · L Encéphale · doi:10.1016/j.encep.2018.09.005 · Cited by 23
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodríguez, C. I., Kalin, N. H., & McDonald, W. M. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19104 · Cited by 28
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Dai, D., Miller, C., Valdivia, V., Boyle, B. W., Bolton, P., Li, S., Seiner, S. J., & Meisner, R. C. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03789-3 · Cited by 24
Xu, S., Yang, J., Li, J., Zhang, M., Sun, J., Liu, Q., & Yang, J. (2024) · BMC Anesthesiology · doi:10.1186/s12871-023-02398-1 · Cited by 22
Brenner, L. A., Capaldi, V., Constans, J., Dobscha, S., Fuller, M., Matarazzo, B., McGraw, K., Richter, K., Sall, J., Smolenski, D., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01938 · Cited by 22
Gallay, C. C., Forsyth, G., Can, A., Dutton, M., Jamieson, D., Jensen, E., Hermens, D. F., Bennett, M. R., & Lagopoulos, J. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111369 · Cited by 21
Li, W.-C., Wang, C.-Y., Lan, X.-F., Fu, L., Zhang, F., Ye, Y., Liu, H., Wu, K., Zhou, Y.-L., & Ning, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.122 · Cited by 20
Future of paediatric sedation: towards a unified goal of improving practice
Mason, K., & Seth, N. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.01.025 · Cited by 19
Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review
Memon, R. I., Naveed, S., Faquih, A. E., Fida, A., Abbas, N., Chaudhary, A. M. D., & Qayyum, Z. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09830-6 · Cited by 22
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Nemeroff, C. B. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18010014 · Cited by 19
Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression
Jelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Whooley, E., McDonagh, K., McDonogh, S., Loughran, O., Shackleton, E., Igoe, A., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3019 · Cited by 19
Oral ketamine may offer a solution to the ketamine conundrum
Dutton, M., Can, A., Lagopoulos, J., & Hermens, D. F. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06480-x · Cited by 22
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 20
Hirota, K., & Lambert, D. G. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.08.020 · Cited by 19
Glutamine and New Pharmacological Targets to Treat Suicidal Ideation
Jiménez-Treviño, L., González-Blanco, L., Alvarez-Vázquez, C., Rodríguez-Revuelta, J., & Sáiz, P. A. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_168 · Cited by 19
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Nobile, B., Gourguechon-Buot, E., Olié, É., & Courtet, P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119854 · Cited by 20
Clinical overview of NMDA-R antagonists and clinical practice
Davoudian, P. A., & Wilkinson, S. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.004 · Cited by 19
Translating Interventional Neuroscience to Suicide: It’s About Time
Barredo, J., Bozzay, M. L., Primack, J. M., Schatten, H. T., Armey, M. F., Carpenter, L. L., & Philip, N. S. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.013 · Cited by 21
Li, W., Wang, C., Lan, X., Fu, L., Zhang, F., Ye, Y., Liu, H., Wu, K., Lao, G., Chen, J., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.937145 · Cited by 18
Wolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 22
Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression
Dębowska, W., Więdłocha, M., Dębowska, M. D., Kownacka, Z., Marcinowicz, P., & Szulc, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267647 · Cited by 23
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 19
MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail
Bedi, G., Cotton, S. M., Guerin, A. A., & Jackson, H. J. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221127186 · Cited by 18
Prospective association of psychological pain and hopelessness with suicidal thoughts
Ballard, E. D., Farmer, C. A., Gerner, J., Bloomfield-Clagett, B., Park, L. T., & Zarate, C. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.033 · Cited by 16
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation
Mitchell, J., Hermens, D. F., Bennett, M. R., Can, A., & Lagopoulos, J. (2023) · CNS Drugs · doi:10.1007/s40263-022-00984-4 · Cited by 18
Emerging Anesthetic Nanomedicines: Current State and Challenges
Zhang, S., Wang, Y., Zhang, S., Huang, C., Ding, Q., Xia, J., Wu, D., & Gao, W. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417855 · Cited by 19
Calder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 24
Ketamine: A Review for Clinicians
Sanacora, G., & Katz, R. R. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180012 · Cited by 17
Blinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 23
Blinding Integrity in Psychedelic Randomized Clinical Trials
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 19
Recent Advances in the Development of Antidepressants Targeting the Purinergic P2X7 Receptor
Lee, S., Ha, H., Jang, J., & Byun, Y. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220629141418 · Cited by 16
Liu, H., Lan, X., Wang, C., Zhang, F., Fu, L., Li, W., Ye, Y., Hu, Z., Chao, Z., Ning, Y., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04388-y · Cited by 18
Goel, K., Thapliyal, S., Kharb, R., Joshi, G., Negi, A., & Kumar, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092208 · Cited by 17
Grunebaum, M. F., Mann, J. J., Galfalvy, H., & Gibbons, R. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.602976 · Cited by 16
Self-citationPredictors on workplace suicidal ideation: from a social interaction perspective
Tan, L., & Xia, T. (2021) · Current Psychology · doi:10.1007/s12144-021-01928-9 · Cited by 16
Antisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder
Pathak, U., Ahuja, S. K., Dwivedi, R., Mishra, N., Kumar, P. J., Mishra, D. K., & Singh, R. (2021) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_80_21 · Cited by 19
Sobanski, T., Peikert, G., Kastner, U. W., & Wagner, G. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i9.1115 · Cited by 17
Zhou, Y., Wang, C., Lan, X., Li, W., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.779326 · Cited by 16
Driver, C., Jackson, T., Lagopoulos, J., & Hermens, D. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110609 · Cited by 17
Stress, mental disorder and ketamine as a novel, rapid acting treatment
Dutton, M., Can, A., Lagopoulos, J., & Hermens, D. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.006 · Cited by 17
Chen, K. S., Dwivedi, Y., & Shelton, R. C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.054 · Cited by 15
Ohtani, Y., Tani, H., Nomoto‐Takahashi, K., Yatomi, T., Yonezawa, K., Tomiyama, S., Nagai, N., Kusudo, K., Honda, S., Moriyama, S., et al. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13734 · Cited by 14
Genome-wide methylome-based molecular pathologies associated with depression and suicide
Dwivedi, Y., Roy, B., & Korla, P. K. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02040-9 · Cited by 16
Zhao, F., Pan, H., Li, N., Chen, X., Zhang, H., Mao, N., & Ren, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.976229 · Cited by 14
Underwood, M. D., Bakalian, M. J., Johnson, V. L., Kassir, S. A., Ellis, S. P., Mann, J. J., & Arango, V. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa009 · Cited by 13
Self-citationTucciarone, J., Bandeira, I. D., Blasey, C. M., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., et al. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250840 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Xu, W., Wang, P., Wang, D., Liu, K., Zhang, S., Zhao, W., & Liu, G. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0763 · Cited by 13
Ketamine for suicidality: An umbrella review
Shamabadi, A., Ahmadzade, A., & Hasanzadeh, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15360 · Cited by 14
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Alario, A. A., & Niciu, M. J. (2022) · Chronic Stress · doi:10.1177/24705470221128017 · Cited by 17
Ketamine for acute suicidality in the emergency department: A systematic review
Maguire, L. A., Bullard, T., & Papa, L. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.12.088 · Cited by 16
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
An urgent need for rapid anti-suicidal drugs
Courtet, P., Nobile, B., Guillaume, S., & Olié, É. (2020) · French Journal of Psychiatry · doi:10.1016/j.fjpsy.2020.02.003 · Cited by 13
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 15
Metadata
- Authors
- Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., & Mann, J. J.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the Molecular Imaging and Neuropathology Division, Department of Psychiatry, and the Department of Anesthesiology, Columbia University Medical Center and New York State Psychiatric Institute, New York.
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2018-04-01
- Volume
- 175
- Issue
- 4
- Pages
- 327-335
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5880701
- OpenAlex
- W2771797851
- Cited by
- 431
- References
- 47
- Citations by year
- 2026: 31 · 2025: 45 · 2024: 52 · 2023: 57 · 2022: 62 · 2021: 54 · 2020: 55 · 2019: 43 · 2018: 31
- FWCI
- 24.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH096784)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, midazolam, suicidal ideation, major depressive disorder, rapid-acting antidepressants, adjunctive pharmacotherapy, suicide risk reduction, antidepressant effects, mediation analysis
- MeSH terms
- Behavior Rating Scale, Suicide Prevention, Adult, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Male, Midazolam, Middle Aged, Suicide, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
